Readoutin 14d
Biohaven Therapeutics Ltd. — BHV-7000
Phase 3 primary completion: A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy.
- Date
- Dec 2026
- Type
- Readout
- Indication
- Focal Epilepsy
Readoutin 14d
Phase 3 primary completion: A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy.
The weekly brief is free. Pro adds reminders 7 days and 1 day before.